The Zhitong Finance App learned that Biosetu-B (02315) rose more than 6% in early trading. As of press release, it had risen 4.64% to HK$52.95, with a turnover of HK$9.3465 million.
According to news, in the first half of 2026, Baiosetu-B achieved operating income of 941 million yuan, an increase of 51.60% over the previous year, net profit to mother of 241 million yuan, an increase of 402.29% over the previous year, and net profit after deduction of 197 million yuan, an increase of 591.53% over the previous year. It is worth mentioning that in the first half of 2026, the company's preclinical product and service business, which is centered on sales of innovative animal models, achieved operating income of 723 million yuan, an increase of 57.94% over the previous year, and a gross margin of 75.22%. Among them, the model animal business achieved revenue of 446 million yuan, an increase of 62.44% over the previous year, and a gross margin of 82.30%.
Western Securities pointed out that Baiosetu-B continues to upgrade the 1000 Mouse Immunity Program. At present, it has completed evaluation and research on about 1,200 targets and has basically developed antibodies for all targets, forming a “shelf” with over one million antibodies and epitope-rich antibody molecular sequences. The company officially released RenSuper Workstation, a next-generation AI-driven antibody discovery platform, in May 2026, and successfully built a three-drive architecture of a “real antibody sequence library+AI+automated intelligent manufacturing platform”.